AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38426909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully Closed-Loop Insulin Delivery
Number of subjects: 0
Study 38427038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri NCIMB 30351 drops (5 drops, 2 times a day)
Number of subjects: 90
Study 38427038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 38427039 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of routine gastric residual measurement
Number of subjects: 88
Study 38427039 — intervention group
Group type: COMPARATOR
Intervention: Routine gastric residual measurement
Number of subjects: 88
Study 38427076 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion during a hyperinsulinaemic-euglycaemic clamp in participants with type 1 diabetes
Number of subjects: 27
Study 38427076 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline infusion during a hyperinsulinaemic-euglycaemic clamp in healthy participants
Number of subjects: 27
Study 38427220 — intervention group
Group type: EXPERIMENTAL
Intervention: Omidubicel-onlv (20% use)
Number of subjects: 10000
Study 38427220 — intervention group
Group type: COMPARATOR
Intervention: Omidubicel-onlv
Number of subjects: 10000
Study 38427269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative Learning (CL) with technology support
Number of subjects: 813
Study 38427322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination A (flexible single-channel EEG headband + actigraphy)
Number of subjects: 23
Study 38427322 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible headband alone
Number of subjects: 23
Study 38427322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination B (rigid single-channel EEG headband + actigraphy)
Number of subjects: 23
Study 38427322 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid headband alone
Number of subjects: 23
Study 38427366 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-y gastric bypass (RYGB)
Number of subjects: 123
Study 38427368 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk-oriented exercises
Number of subjects: 30
Study 38427368 — intervention group
Group type: COMPARATOR
Intervention: Whole-body vibration
Number of subjects: 30
Study 38427387 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PA instability (within-person)
Number of subjects: 24
Study 38427485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 0
Study 38427485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38427753 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA mutations of KRAS, TP53, DIS3, BRAF, NRAS, and ATM
Number of subjects: 261
Study 38427753 — intervention group
Group type: EXPERIMENTAL
Intervention: BMPC mutations of TP53 and KRAS
Number of subjects: 261
Study 38427753 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutations detected in both BMPC and ctDNA
Number of subjects: 261
Study 38427753 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of ctDNA mutations in 6 relevant genes
Number of subjects: 261
Study 38427753 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index using ctDNA mutations, plasma DNA concentration, and clinical factors
Number of subjects: 261
Study 38427923 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38427930 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-developed test (LDT) for HRD
Number of subjects: 91
Study 38427930 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional RAD51 assay
Number of subjects: 91
Study 38427930 — intervention group
Group type: COMPARATOR
Intervention: CDx HRD testing
Number of subjects: 91
Study 38428259 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg oral dose
Number of subjects: 20
Study 38428265 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (Pemetrexed Cisplatin)
Number of subjects: 134
Study 38428265 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized treatment based on EGFR mutation (Erlotinib) and ERCC1 expression
Number of subjects: 134
Study 38428265 — intervention group
Group type: COMPARATOR
Intervention: KRAS mutations
Number of subjects: 134
Study 38428265 — intervention group
Group type: COMPARATOR
Intervention: Isolated STK11/LKB1 mutations
Number of subjects: 134
Study 38428428 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone treatment (900 mg/day) for 24 months
Number of subjects: 199
Study 38428428 — intervention group
Group type: COMPARATOR
Intervention: Natural history control cohort
Number of subjects: 199
Study 38428649 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline values of quinolinic acid, PAr, and HKr
Number of subjects: 422
Study 38428649 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline concentrations of neopterin and 3-hydroxykynurenine
Number of subjects: 422
Study 38428649 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of xanthurenic acid
Number of subjects: 422
Study 38428649 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of neopterin and lower values of pyridoxal 5́-phosphate
Number of subjects: 422
Study 38428649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower concentrations of picolinic acid
Number of subjects: 422
Study 38428681 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiation therapy (SBRT) at 42.5 Gy in 5 fractions
Number of subjects: 9
Study 38428681 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiation therapy (SBRT) at 40 Gy (DL1)
Number of subjects: 9
Study 38428681 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiation therapy (SBRT) at 42.5 Gy (DL2)
Number of subjects: 9
Study 38428681 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiation therapy (SBRT)
Number of subjects: 9
Study 38428740 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss dietary intervention
Number of subjects: 536
Study 38428741 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy intake (EI) biomarker developed from doubly labeled water (DLW) total energy expenditure (TEE) and weight variation during a 2-week DLW protocol period.
Number of subjects: 1284
Study 38428741 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy intake (EI) among participants with stable or increasing weight.
Number of subjects: 1284
Study 38428741 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy intake (EI) among participants with preceding weight loss.
Number of subjects: 1284
Study 38428970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active αTMS
Number of subjects: 44
Study 38428970 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 44
Study 38428980 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE/sPAP < 0.40 mm/mmHg
Number of subjects: 333
Study 38429056 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM) accompanied by access to the web-based cardiovascular educational portal (Kvatchii)
Number of subjects: 200
Study 38429056 — intervention group
Group type: COMPARATOR
Intervention: Home blood pressure monitoring (HBPM) alone
Number of subjects: 200
Study 38429067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloplegic objective wavefront-based refraction
Number of subjects: 84
Study 38429067 — intervention group
Group type: COMPARATOR
Intervention: Non-cycloplegic objective wavefront-based refraction
Number of subjects: 84
Study 38429067 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective refraction with cyclopentolate
Number of subjects: 84
Study 38429079 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based trajectory models (GBTM) with 4 distinct trajectories
Number of subjects: 343
Study 38429079 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FACT-PWB
Number of subjects: 343
Study 38429085 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-cancer early detection (MCED) screening programme
Number of subjects: 0
Study 38429253 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily)
Number of subjects: 40
Study 38429253 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (1 mg/kg twice daily)
Number of subjects: 40
Study 38429253 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban and Enoxaparin
Number of subjects: 40
Study 38429253 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety outcomes
Number of subjects: 40
Study 38429311 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-negative patients during CRT
Number of subjects: 42
Study 38429311 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-negative patients post-CRT
Number of subjects: 42
Study 38429311 — intervention group
Group type: COMPARATOR
Intervention: Detectable ctDNA during CRT
Number of subjects: 42
Study 38429311 — intervention group
Group type: COMPARATOR
Intervention: Detectable ctDNA post-CRT
Number of subjects: 42
Study 38429311 — intervention group
Group type: EXPERIMENTAL
Intervention: High bTMB levels during CRT
Number of subjects: 42
Study 38429618 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Economic (BE) intervention delivered by a registered nurse and social worker for three months
Number of subjects: 331
Study 38429618 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 331
Study 38429621 — intervention group
Group type: EXPERIMENTAL
Intervention: AChE activity in viral sepsis
Number of subjects: 108
Study 38429621 — intervention group
Group type: EXPERIMENTAL
Intervention: BChE activity in viral sepsis
Number of subjects: 108
Study 38429621 — intervention group
Group type: COMPARATOR
Intervention: AChE activity in nonviral sepsis
Number of subjects: 108
Study 38429621 — intervention group
Group type: COMPARATOR
Intervention: BChE activity in nonviral sepsis
Number of subjects: 108
Study 38429621 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 108
Study 38429839 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus Maze Out
Number of subjects: 94
Study 38429839 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 94
Study 38430084 — intervention group
Group type: EXPERIMENTAL
Intervention: ReDS-guided decongestion strategy (discharge criteria requiring an ReDS value of ≤35%)
Number of subjects: 100
Study 38430084 — intervention group
Group type: COMPARATOR
Intervention: Routine care strategy (discharge criteria based on current clinical practice)
Number of subjects: 100
Study 38430084 — intervention group
Group type: EXPERIMENTAL
Intervention: ReDS-guided decongestion strategy
Number of subjects: 100
Study 38430246 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal-CD8
Number of subjects: 889
Study 38430246 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 889
Study 38430272 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (0.3 mg/kg intravenous every 12 weeks)
Number of subjects: 67
Study 38430272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 38430288 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person intervention
Number of subjects: 32
Study 38430288 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 32
Study 38430309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesional skin of LP patients
Number of subjects: 30
Study 38430309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlesional skin of LP patients
Number of subjects: 30
Study 38430309 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 38430375 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 0
Study 38430375 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab monotherapy
Number of subjects: 0
Study 38430375 — intervention group
Group type: COMPARATOR
Intervention: EXTREME regimen
Number of subjects: 0
Study 38430375 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab monotherapy and durvalumab plus tremelimumab
Number of subjects: 0
Study 38430402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 806
Study 38430402 — intervention group
Group type: COMPARATOR
Intervention: Antimuscarinics
Number of subjects: 806
Study 38430405 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4635 + durvalumab
Number of subjects: 59
Study 38430405 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4635 + oleclumab
Number of subjects: 59
Study 38430405 — intervention group
Group type: COMPARATOR
Intervention: AZD4635
Number of subjects: 59
Study 38430413 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental new technology (NT) stems
Number of subjects: 53
Study 38430413 — intervention group
Group type: COMPARATOR
Intervention: Standard (STD) stems
Number of subjects: 53
Study 38430550 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis group (OP)
Number of subjects: 0
Study 38430550 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 38431043 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy
Number of subjects: 2320
Study 38431043 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2320
Study 38431079 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-derived PCWP using left atrial volume (LAV) at rest
Number of subjects: 75
Study 38431079 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-derived PCWP using left atrial volume (LAV) during exercise-stress
Number of subjects: 75
Study 38431079 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-derived PCWP using left atrial area (LAA) at rest
Number of subjects: 75
Study 38431079 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-derived PCWP using left atrial area (LAA) during exercise-stress
Number of subjects: 75
Study 38431079 — intervention group
Group type: EXPERIMENTAL
Intervention: LAV PCWP during exercise-stress
Number of subjects: 75
Study 38431079 — intervention group
Group type: COMPARATOR
Intervention: LAV PCWP (rest) vs LAV PCWP (stress)
Number of subjects: 75
Study 38431079 — intervention group
Group type: COMPARATOR
Intervention: LAA PCWP (rest) vs LAA PCWP (stress)
Number of subjects: 75
Study 38431102 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided elastography (EUS-EG)
Number of subjects: 53
Study 38431103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation system (CBAS)
Number of subjects: 15
Study 38431130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise fitness and intensive pelvic floor muscle training program
Number of subjects: 106
Study 38431130 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study 38431131 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of hydrocortisone parenterally every 8 hours for 3 days
Number of subjects: 0
Study 38431131 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 38431131 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of hydrocortisone
Number of subjects: 0
Study 38431133 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored medication adherence-promotion intervention
Number of subjects: 0
Study 38431134 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus tFOCUS (12-week intervention including a patient-facing mHealth app, clinician-facing web dashboard, and mHealth aftercare advisors)
Number of subjects: 180
Study 38431134 — intervention group
Group type: COMPARATOR
Intervention: TAU plus standard discharge planning and aftercare (CHECK-IN)
Number of subjects: 180
Study 38431156 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCov-19) two-dose primary series
Number of subjects: 4500000
Study 38431284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) participation
Number of subjects: 1682
Study 38431284 — intervention group
Group type: EXPERIMENTAL
Intervention: High optimism levels
Number of subjects: 1682
Study 38431284 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors (anxiety, pessimism, resilience)
Number of subjects: 1682
Study 38431295 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care supplemented with a harm reduction kiosk
Number of subjects: 750
Study 38431295 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (fixed-site, staffed syringe service programme)
Number of subjects: 750
Study 38431296 — intervention group
Group type: EXPERIMENTAL
Intervention: High societal costs (top 25th percentile) after 1 year of follow-up
Number of subjects: 549
Study 38431296 — intervention group
Group type: EXPERIMENTAL
Intervention: High costs related to healthcare utilisation after 1 year of follow-up
Number of subjects: 549
Study 38431296 — intervention group
Group type: EXPERIMENTAL
Intervention: High costs related to productivity loss after 1 year of follow-up
Number of subjects: 549
Study 38431300 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 30
Study 38431300 — intervention group
Group type: COMPARATOR
Intervention: Contralateral shoulders (control)
Number of subjects: 30
Study 38431445 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemin (4 mg/kg)
Number of subjects: 282
Study 38431445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 38431766 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic or topical interventions (specifics not provided)
Number of subjects: 16838
Study 38431766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggravating factors (foods, seasonal changes, psychological factors)
Number of subjects: 16838
Study 38431766 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities (chronic urticaria, food allergies, diabetes)
Number of subjects: 16838
Study 38431766 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of AD onset (≥60 years)
Number of subjects: 16838
Study 38431766 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic rhinitis and hypertension
Number of subjects: 16838
Study 38431848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 0
Study 38431848 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 0
Study 38431848 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal problems and social functioning
Number of subjects: 0
Study 38432027 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 80 years and older
Number of subjects: 26193
Study 38432027 — intervention group
Group type: COMPARATOR
Intervention: Patients under 80 years
Number of subjects: 26193
Study 38432027 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (≥80 years)
Number of subjects: 26193
Study 38432233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (600 mg orally every 8 h)
Number of subjects: 30
Study 38432233 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid (500 mg amoxicillin and 125 mg clavulanic acid orally every 8 h)
Number of subjects: 30
Study 38432236 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-targeted plus patient-targeted feedback
Number of subjects: 1030
Study 38432236 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-targeted feedback
Number of subjects: 1030
Study 38432236 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 1030
Study 38432247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 500 mg/m2
Number of subjects: 82
Study 38432247 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 82
Study 38432471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing Social Functioning for older Veterans with PTSD (ESVP) intervention
Number of subjects: 0
Study 38432471 — intervention group
Group type: COMPARATOR
Intervention: Support group control
Number of subjects: 0
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent dietary intake of fiber
Number of subjects: 358
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual dietary intake of fiber
Number of subjects: 358
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual soluble fiber intake
Number of subjects: 358
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent legume intake
Number of subjects: 358
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual legume intake
Number of subjects: 358
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent vegetable intake
Number of subjects: 358
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual vegetable intake
Number of subjects: 358
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent Healthy Eating Index (HEI) scores
Number of subjects: 358
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index scores for recent intake
Number of subjects: 358
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent and habitual fiber, legume, vegetable, and fruit intake (excluding clinically elevated calprotectin)
Number of subjects: 358
Study 38432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent total HEI score
Number of subjects: 358
Study 38432713 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cup of freeze-dried blueberry powder
Number of subjects: 115
Study 38432713 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 115
Study 38432714 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplementation (daily oral multiple micronutrient supplementation including 50 μg/d of vitamin B-12)
Number of subjects: 412
Study 38432714 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal supplementation (postnatal supplement including 50 μg/d of vitamin B-12)
Number of subjects: 412
Study 38432714 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) during prenatal or postnatal periods
Number of subjects: 412
Study 38432715 — intervention group
Group type: EXPERIMENTAL
Intervention: AAIM tool for diagnosing malnutrition
Number of subjects: 290
Study 38432810 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 37
Study 38432810 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling Recovery (FRR)
Number of subjects: 37
Study 38432810 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 37